CoChat
Sign Up
Cited by 450Antibiotics Pharmacokinetics and EfficacyAntibiotic Use and ResistanceNeutropenia and Cancer Infections

Single or multiple daily doses of aminoglycosides: a meta-analysis

Open access
Barza, Michael, Ioannidis, John Pa, Cappelleri, Joseph C, Lau, Joseph·1996·BMJ
DOI 10.1136/bmj.312.7027.338PMC PMC2350289
Open this paper in CoChat — free account

Abstract

Objective : To assess relative efficacy and toxicity of aminoglycosides given by single daily dose compared with multiple daily doses. Design : Meta-analysis of 21 randomised trials identified through MEDLARS (1966 to January 1995). Data were overviewed with fixed effects and random effects models and with meta-regression analysis. Subjects : Total of 3091 patients with bacterial infection, most without pre-existing renal disease. Interventions : Patients were randomised to receive aminoglycosides once daily or multiple times daily with similar total daily dose. Main outcome measures : Clinical failure of treatment, nephrotoxicity, ototoxicity, and mortality. Results : Single daily dose regimen produced a non-significant decrease in risk of antibiotic failures (random effects risk ratio 0.83 (95% confidence interval 0.57 to 1.21)). Benefit of once daily dosing was greater when the percentage of pseudomonas isolates in a trial was larger. Once daily administration reduced risk of nephrotoxicity (fixed effects risk ratio 0.74 (0.54 to 1.00)). Similar trends were noted for patients with febrile neutropenia and for children. There was no significant difference in ototoxicity between the two dosing regimens, but the power of the pooled trials to detect a meaningful difference was low. There was no significant difference in mortality. Conclusions : Once daily administration of aminoglycosides in patients without pre-existing renal impairment is as effective as multiple daily dosing, has a lower risk of nephrotoxicity, and no greater risk of ototoxicity. Given the additional convenience and reduced cost, once daily dosing should be the preferred mode of administration. Key messages: Key messages This meta-analysis shows that single daily doses of aminoglycosides were about 25% less nephrotoxic than and at least as effective clinically as multiple daily doses The dosing schedule did not significantly affect the incidence of ototoxicity, but the power to detect a difference was small Once daily dosing was non-significantly more effective in patients with febrile neutropenia and in children, and the apparent benefit of once daily dosing increased with increasing proportion of pseudomonas isolates in a trial Besides the convenience of once daily dosing, reduced costs of drug administration and omission of measurements of peak antibiotic concentrations should result in substantial cost savings

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmj.312.7027.338

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Barza 1996 performed a meta-analysis of single versus multiple doses of aminoglycoside for the treatment of various infections, and the conclusions support a once-daily regimen.

    “Barza 1996 performed a meta-analysis of single versus multiple doses of aminoglycoside for the treatment of various infections, and the conclusions support a once-daily regimen.”

    From Antibiotic regimens for postpartum endometritis (2015) · cites this paper as Barza 1996

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 47

  1. Anderson E. T., Young L. S., Hewitt W. L. Simultaneous antibiotic levels in "breakthrough" gram-negative rod bacteremia. Am J Med. 1976 Oct;61(4):493–497. doi: 10.1016/0002-9343(76)90328-4. [DOI] [PubMed] [Google Scholar] · DOI
  2. Aronoff G. R., Pottratz S. T., Brier M. E., Walker N. E., Fineberg N. S., Glant M. D., Luft F. C. Aminoglycoside accumulation kinetics in rat renal parenchyma. Antimicrob Agents Chemother. 1983 Jan;23(1):74–78. doi: 10.1128/aac.23.1.74. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  3. Bamonte F., Dionisotti S., Gamba M., Ongini E., Arpini A., Melone G. Relation of dosing regimen to aminoglycoside ototoxicity: evaluation of auditory damage in the guinea pig. Chemotherapy. 1990;36(1):41–50. doi: 10.1159/000238747. [DOI] [PubMed] [Google Scholar] · DOI
  4. Bennett W. M., Plamp C. E., Gilbert D. N., Parker R. A., Porter G. A. The influence of dosage regimen on experimental gentamicin nephrotoxicity: dissociation of peak serum levels from renal failure. J Infect Dis. 1979 Oct;140(4):576–580. doi: 10.1093/infdis/140.4.576. [DOI] [PubMed] [Google Scholar] · DOI
  5. Blaser J., Stone B. B., Groner M. C., Zinner S. H. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother. 1987 Jul;31(7):1054–1060. doi: 10.1128/aac.31.7.1054. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  6. Brummett R. E., Fox K. E., Bendrick T. W., Himes D. L. Ototoxicity of tobramycin, gentamicin, amikacin and sisomicin in the guinea pig. J Antimicrob Chemother. 1978 May;4 (Suppl A):73–83. doi: 10.1093/jac/4.suppl_a.73. [DOI] [PubMed] [Google Scholar] · DOI
  7. Chalmers T. C., Lau J. Meta-analytic stimulus for changes in clinical trials. Stat Methods Med Res. 1993;2(2):161–172. doi: 10.1177/096228029300200204. [DOI] [PubMed] [Google Scholar] · DOI
  8. Davis R. R., Brummett R. E., Bendrick T. W., Himes D. L. Dissociation of maximum concentration of kanamycin in plasma and perilymph from ototoxic effect. J Antimicrob Chemother. 1984 Sep;14(3):291–302. doi: 10.1093/jac/14.3.291. [DOI] [PubMed] [Google Scholar] · DOI
  9. Feld R., Rachlis A., Tuffnell P. G., Duncan I., Moran L., Pinfold P., DeBoer G. Empiric therapy for infections in patients with granulocytopenia. Continuous v interrupted infusion of tobramycin plus cefamandole. Arch Intern Med. 1984 May;144(5):1005–1010. [PubMed] [Google Scholar]
  10. Gerber A. U., Feller-Segessenmann C. In-vivo assessment of in-vitro killing patterns of Pseudomonas aeruginosa. J Antimicrob Chemother. 1985 Jan;15 (Suppl A):201–206. doi: 10.1093/jac/15.suppl_a.201. [DOI] [PubMed] [Google Scholar] · DOI
  11. Gerber A. U., Kozak S., Segessenmann C., Flückiger U., Bangerter T., Greter U. Once-daily versus thrice-daily administration of netilmicin in combination therapy of Pseudomonas aeruginosa infection in a man-adapted neutropenic animal model. Eur J Clin Microbiol Infect Dis. 1989 Mar;8(3):233–237. doi: 10.1007/BF01965266. [DOI] [PubMed] [Google Scholar] · DOI
  12. Gibson J., Johnson L., Snowdon L., Joshua D., Young G., MacLeod C., Sader C., Iland H., Vincent P., Kronenberg H. Single daily ceftriaxone and tobramycin in the empirical management of febrile neutropenic patients: a randomised trial. Int J Hematol. 1993 Aug;58(1-2):63–72. [PubMed] [Google Scholar]
  13. Gilbert D. N. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother. 1991 Mar;35(3):399–405. doi: 10.1128/aac.35.3.399. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  14. Gonzalez P., Aguado J. M., Martin M. A., Fernandez-Chacon T., Ortuño B. Once-daily aminoglycoside dosing. Lancet. 1993 Apr 3;341(8849):895–895. [PubMed] [Google Scholar]
  15. Herscovici L., Grise G., Thauvin C., Lemeland J. F., Fillastre J. P. Efficacy and safety of once daily versus intermittent dosing of tobramycin in rabbits with acute pyelonephritis. Scand J Infect Dis. 1988;20(2):205–212. doi: 10.3109/00365548809032439. [DOI] [PubMed] [Google Scholar] · DOI
  16. Hollender L. F., Bahnini J., De Manzini N., Lau W. Y., Fan S. T., Hermansyur K., Benny P., Husni A. N., Sutjipto, Lorber R. R. A multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra-abdominal infections. J Antimicrob Chemother. 1989 May;23(5):773–783. doi: 10.1093/jac/23.5.773. [DOI] [PubMed] [Google Scholar] · DOI
  17. Kapusnik J. E., Hackbarth C. J., Chambers H. F., Carpenter T., Sande M. A. Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia. J Infect Dis. 1988 Jul;158(1):7–12. doi: 10.1093/infdis/158.1.7. [DOI] [PubMed] [Google Scholar] · DOI
  18. Klastersky J., Prévost J. M., Meunier-Carpentier F., Daneau D., Gerard M. Comparative trial of single-dose versus twice-daily sisomicin in bacteriuric patients. J Clin Pharmacol. 1977 Aug-Sep;17(8-9):520–528. doi: 10.1002/j.1552-4604.1977.tb05645.x. [DOI] [PubMed] [Google Scholar] · DOI
  19. Labovitz E., Levison M. E., Kaye D. Single-dose daily gentamicin therapy in urinary tract infection. Antimicrob Agents Chemother. 1974 Oct;6(4):465–470. doi: 10.1128/aac.6.4.465. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  20. Maller R., Ahrne H., Holmen C., Lausen I., Nilsson L. E., Smedjegård J. Once- versus twice-daily amikacin regimen: efficacy and safety in systemic gram-negative infections. Scandinavian Amikacin Once Daily Study Group. J Antimicrob Chemother. 1993 Jun;31(6):939–948. doi: 10.1093/jac/31.6.939. [DOI] [PubMed] [Google Scholar] · DOI
  21. Marik P. E., Lipman J., Kobilski S., Scribante J. A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients. J Antimicrob Chemother. 1991 Nov;28(5):753–764. doi: 10.1093/jac/28.5.753. [DOI] [PubMed] [Google Scholar] · DOI
  22. Mauracher E. H., Lau W. Y., Kartowisastro H., Ong K. H., Genato V. X., Limson B., Yusi G. M., Liu C. Y., Suwangool P. Comparison of once-daily and thrice-daily netilmicin regimens in serious systemic infections: a multicenter study in six Asian countries. Clin Ther. 1989 Sep-Oct;11(5):604–613. [PubMed] [Google Scholar]
  23. McCormack J. P., Jewesson P. J. A critical reevaluation of the "therapeutic range" of aminoglycosides. Clin Infect Dis. 1992 Jan;14(1):320–339. doi: 10.1093/clinids/14.1.320. [DOI] [PubMed] [Google Scholar] · DOI
  24. Mendes da Costa P., Kaufman L. Amikacin once daily plus metronidazole versus amikacin twice daily plus metronidazole in colorectal surgery. Hepatogastroenterology. 1992 Aug;39(4):350–354. [PubMed] [Google Scholar]
  25. Moore R. D., Smith C. R., Lietman P. S. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis. 1984 Mar;149(3):443–448. doi: 10.1093/infdis/149.3.443. [DOI] [PubMed] [Google Scholar] · DOI
  26. Mordenti J. J., Quintiliani R., Nightingale C. H. Combination antibiotic therapy: comparison of constant infusion and intermittent bolus dosing in an experimental animal model. J Antimicrob Chemother. 1985 Jan;15 (Suppl A):313–321. doi: 10.1093/jac/15.suppl_a.313. [DOI] [PubMed] [Google Scholar] · DOI
  27. Noone P., Parsons T. M., Pattison J. R., Slack R. C., Garfield-Davies D., Hughes K. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J. 1974 Mar 16;1(5906):477–481. doi: 10.1136/bmj.1.5906.477. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  28. Nordström L., Lerner S. A. Single daily dose therapy with aminoglycosides. J Hosp Infect. 1991 Jun;18 (Suppl A):117–129. doi: 10.1016/0195-6701(91)90013-x. [DOI] [PubMed] [Google Scholar] · DOI
  29. Nordström L., Ringberg H., Cronberg S., Tjernström O., Walder M. Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity? J Antimicrob Chemother. 1990 Jan;25(1):159–173. doi: 10.1093/jac/25.1.159. [DOI] [PubMed] [Google Scholar] · DOI
  30. Oakes M. The logic and role of meta-analysis in clinical research. Stat Methods Med Res. 1993;2(2):147–160. doi: 10.1177/096228029300200203. [DOI] [PubMed] [Google Scholar] · DOI
  31. Olier B., Viotte G., Morin J. P., Fillastre J. P. Influence of dosage regimen on experimental tobramycin nephrotoxicity. A biochemical approach. Chemotherapy. 1983;29(6):385–394. doi: 10.1159/000238225. [DOI] [PubMed] [Google Scholar] · DOI
  32. Powell S. H., Thompson W. L., Luthe M. A., Stern R. C., Grossniklaus D. A., Bloxham D. D., Groden D. L., Jacobs M. R., DiScenna A. O., Cash H. A. Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J Infect Dis. 1983 May;147(5):918–932. doi: 10.1093/infdis/147.5.918. [DOI] [PubMed] [Google Scholar] · DOI
  33. Prins J. M., Büller H. R., Kuijper E. J., Tange R. A., Speelman P. Once versus thrice daily gentamicin in patients with serious infections. Lancet. 1993 Feb 6;341(8841):335–339. doi: 10.1016/0140-6736(93)90137-6. [DOI] [PubMed] [Google Scholar] · DOI
  34. Reiner N. E., Bloxham D. D., Thompson W. L. Nephrotoxicity of gentamicin and tobramycin given once daily or continuously in dogs. J Antimicrob Chemother. 1978 May;4 (Suppl A):85–101. doi: 10.1093/jac/4.suppl_a.85. [DOI] [PubMed] [Google Scholar] · DOI
  35. Roosendaal R., Bakker-Woudenberg I. A., van den Berghe-van Raffe M., Vink-van den Berg J. C., Michel B. M. Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats. Eur J Clin Microbiol Infect Dis. 1989 Oct;8(10):878–887. doi: 10.1007/BF01963774. [DOI] [PubMed] [Google Scholar] · DOI
  36. Rozdzinski E., Kern W. V., Reichle A., Moritz T., Schmeiser T., Gaus W., Kurrle E. Once-daily versus thrice-daily dosing of netilmicin in combination with beta-lactam antibiotics as empirical therapy for febrile neutropenic patients. J Antimicrob Chemother. 1993 Apr;31(4):585–598. doi: 10.1093/jac/31.4.585. [DOI] [PubMed] [Google Scholar] · DOI
  37. Sturm A. W. Netilmicin in the treatment of gram-negative bacteremia: single daily versus multiple daily dosage. J Infect Dis. 1989 May;159(5):931–937. doi: 10.1093/infdis/159.5.931. [DOI] [PubMed] [Google Scholar] · DOI
  38. Thompson S. G. Controversies in meta-analysis: the case of the trials of serum cholesterol reduction. Stat Methods Med Res. 1993;2(2):173–192. doi: 10.1177/096228029300200205. [DOI] [PubMed] [Google Scholar] · DOI
  39. Tran Ba Huy P., Bernard P., Schacht J. Kinetics of gentamicin uptake and release in the rat. Comparison of inner ear tissues and fluids with other organs. J Clin Invest. 1986 May;77(5):1492–1500. doi: 10.1172/JCI112463. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  40. Van der Auwera P., Meunier F., Ibrahim S., Kaufman L., Derde M. P., Tulkens P. M. Pharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infection. Antimicrob Agents Chemother. 1991 Apr;35(4):640–647. doi: 10.1128/aac.35.4.640. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  41. Vanhaeverbeek M., Siska G., Douchamps J., Herchuelz A. Comparison of the efficacy and safety of amikacin once or twice-a-day in the treatment of severe gram-negative infections in the elderly. Int J Clin Pharmacol Ther Toxicol. 1993 Mar;31(3):153–156. [PubMed] [Google Scholar]
  42. Verpooten G. A., Giuliano R. A., Verbist L., Eestermans G., De Broe M. E. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther. 1989 Jan;45(1):22–27. doi: 10.1038/clpt.1989.4. [DOI] [PubMed] [Google Scholar] · DOI
  43. Viganò A., Principi N., Brivio L., Tommasi P., Stasi P., Villa A. D. Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram-negative pyelonephritis in children. Antimicrob Agents Chemother. 1992 Jul;36(7):1499–1503. doi: 10.1128/aac.36.7.1499. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  44. Vogelman B., Gudmundsson S., Turnidge J., Leggett J., Craig W. A. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis. 1988 Feb;157(2):287–298. doi: 10.1093/infdis/157.2.287. [DOI] [PubMed] [Google Scholar] · DOI
  45. Wood C. A., Norton D. R., Kohlhepp S. J., Kohnen P. W., Porter G. A., Houghton D. C., Brummett R. E., Bennett W. M., Gilbert D. N. The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess. J Infect Dis. 1988 Jul;158(1):13–22. doi: 10.1093/infdis/158.1.13. [DOI] [PubMed] [Google Scholar] · DOI
  46. de Vries P. J., Verkooyen R. P., Leguit P., Verbrugh H. A. Prospective randomized study of once-daily versus thrice-daily netilmicin regimens in patients with intraabdominal infections. Eur J Clin Microbiol Infect Dis. 1990 Mar;9(3):161–168. doi: 10.1007/BF01963832. [DOI] [PubMed] [Google Scholar] · DOI
  47. ter Braak E. W., de Vries P. J., Bouter K. P., van der Vegt S. G., Dorrestein G. C., Nortier J. W., van Dijk A., Verkooyen R. P., Verbrugh H. A. Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med. 1990 Jul;89(1):58–66. doi: 10.1016/0002-9343(90)90099-y. [DOI] [PubMed] [Google Scholar] · DOI

Cited by

Sorted by citations

Authors
Barza, M., Ioannidis, J. P., Cappelleri, J. C., & Lau, J.
Affiliations
Tufts University (US)
ORCID
Ioannidis, John Pa
Venue
BMJ
Publisher
BMJ
Published
1996-02-10
Volume
312
Issue
7027
Pages
338-344
ISSN
  • 0007-1447 (ISSN-L)
  • 0959-8138
  • 1468-5833
DOI
10.1136/bmj.312.7027.338
PMC
PMC2350289
OpenAlex
W1985346266
Cited by
450
References
0
Citations by year
2026: 4 · 2025: 4 · 2024: 5 · 2023: 5 · 2022: 6 · 2021: 11 · 2020: 10 · 2019: 9 · 2018: 13 · 2017: 10 · 2016: 19 · 2015: 10 · 2014: 21 · 2013: 20 · 2012: 9
FWCI
5.50
Type
journal article
Language
en
Open access
Licence
www.bmj.com/company/legal-information/terms-conditions/legal-information/tdm-licencepolicy (tdm)
Locations
  • BMJ (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
Agency for Healthcare Research and Quality (R01-HS07782)
Topics
  • Health Sciences › Medicine › Pharmacology › Antibiotics Pharmacokinetics and Efficacy
  • Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Antibiotic Use and Resistance
  • Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
Keywords
aminoglycosides, once-daily dosing, multiple daily dosing, dosing regimen, nephrotoxicity, ototoxicity, bacterial infection, febrile neutropenia, Pseudomonas, antibiotic efficacy, mortality, children
MeSH terms
Aminoglycosides, Anti-Bacterial Agents, Bacterial Infections, Drug Administration Schedule, Ear Diseases, Humans, Kidney Diseases, Risk Factors, Sensitivity and Specificity, Randomized Controlled Trials as Topic, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review